Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,225 stopped studies mapped to Malignant Genitourinary System Neoplasm and descendants · 88% state a reason
Over the 2,225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07624578 | Evaluation of 68Ga-PSMA PET-CT in the Initial Staging of Advanced Renal Cell Carcinomas -…(REIN-TEP PSMA) | N/A | withdrawn | Jun 3, 2026 | Assistance Publique Hopitaux De Marseille | Due to administrative issues, the study was abandoned before recruitment began. | Enrollment / accrual |
| NCT04981834 | Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate… | N/A | suspended | Jul 29, 2021 | University of Southern California | Accrual goal reached and suspended for analysis purposes. | Enrollment / accrual |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Dec 15, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk… | Other (stated, no rule matched) |
| NCT03275298 | Evolution of the Therapeutic Care in Ovarian Cancer From 2011(ESME OC) | — | suspended | Sep 7, 2017 | UNICANCER | enrolment temporariliy stopped for budget considerations | Enrollment / accrual |
| NCT05714826 | Comprehensive Optimization At-time of Radical Cystectomy Intervention(COARC) | N/A | withdrawn | Feb 6, 2023 | University of Texas Southwestern Medical Center | Recruitment efforts had begun; however, no participants were enrolled, and the trial had been on a… | Enrollment / accrual |
| NCT05903807 | [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer | Phase 2 | terminated | Jun 15, 2023 | Aalborg University Hospital | Early terminated due to low recruitment rate. | Enrollment / accrual |
| NCT06391099 | Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With… | N/A | suspended | Apr 30, 2024 | Ohio State University Comprehensive Cancer Center | pending amendment | Other (stated, no rule matched) |
| NCT02106572 | Therapeutic Instillation of Mistletoe(TIM) | Phase 3 | terminated | Apr 8, 2014 | Abnoba Gmbh | The study was terminated because the required number of patients cannot be reached in the… | Safety / toxicity |
| NCT02316548 | Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating… | Phase 2 | terminated | Dec 15, 2014 | NRG Oncology | Trial will not meet CTEP Early Phase Trial Slow Accrual Guidelines | Enrollment / accrual |
| NCT03324282 | First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder…(GCISAVE) | Phase 2 | terminated | Oct 27, 2017 | University Hospital, Bordeaux | ANSM's refusal to validate ATU requests for avelumab in bladder cancer, Decrease in recruitment,… | Enrollment / accrual |
| NCT01885949 | Tivozanib + Enzalutamide in Adv Prostate Cancer | Phase 2 | terminated | Jun 25, 2013 | Massachusetts General Hospital | Slow accrual | Enrollment / accrual |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to… | Phase 3 | terminated | Oct 19, 2020 | NRG Oncology | Inadequate accrual rate | Enrollment / accrual |
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed… | Phase 3 | withdrawn | Apr 27, 2026 | ImmunityBio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT07111039 | Compare Airway Pressure Release Ventilation (APRV) to Conventional Mechanical Ventila | N/A | withdrawn | Aug 8, 2025 | H. Lee Moffitt Cancer Center and Research Institute | Lack of funding | Funding |
| NCT00183937 | Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer | Phase 2 | terminated | Sep 16, 2005 | University of Southern California | Sponsor stopped study early. | Other (stated, no rule matched) |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT01673581 | Shared Decision Making in Low Risk Prostate Cancer | — | withdrawn | Aug 28, 2012 | Massachusetts General Hospital | Due to unforeseen changes in study personnel, the study was not initiated. | Other (stated, no rule matched) |
| NCT03437941 | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients… | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Corcept Therapeutics | The level of benefit observed did not justify enrolling patients in the Dose Expansion phase of the… | Enrollment / accrual |
| NCT04565496 | Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk…(PEM-PRO) | Phase 2 | withdrawn | Sep 25, 2020 | IRCCS San Raffaele | Study related: Study terminated early due to protocol evolution from neoadjuvant to perioperative… | Enrollment / accrual |
| NCT04716725 | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer | Phase 2 | terminated | Jan 20, 2021 | Thomas Hope | Low accrual | Enrollment / accrual |
| NCT04030559 | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer… | Phase 2 | terminated | Jul 24, 2019 | University of California, Davis | PI choice; poor accrual | Enrollment / accrual |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate,… | — | suspended | Jul 9, 2021 | National Cancer Institute (NCI) | Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and… | Enrollment / accrual |
| NCT07237399 | Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis…(TA-P-OLIM) | — | withdrawn | Nov 19, 2025 | University Hospital, Ghent | No funding | Funding |
| NCT06708936 | KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory… | Early Phase 1 | withdrawn | Nov 29, 2024 | Kousai Bio Co., Ltd. | Due to a strategic adjustment, the company has decided to terminate the project. | Sponsor / business decision |
| NCT07025512 | 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone… | Phase 2 | withdrawn | Jun 17, 2025 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT05820932 | Predicting Cognitive Decline From Androgen Deprivation Therapy(ABC) | — | terminated | Apr 20, 2023 | University of California, San Francisco | Slow Accrual | Enrollment / accrual |
| NCT07573787 | Homoeriodictyol Sodium Mouthwash to Reduce Chemotherapy Induced Bitter Taste Disorders(HED) | N/A | terminated | May 7, 2026 | Christoph Grimm | slow recruitment during COVID pandemia | COVID-19 / pandemic |
| NCT02664389 | Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in…(PANEL) | N/A | terminated | Jan 27, 2016 | University Hospital, Rouen | Difficulty in enrolling patients | Enrollment / accrual |
| NCT01851395 | Rapid Autopsy and Procurement of Cancer Tissue | — | terminated | May 10, 2013 | National Cancer Institute (NCI) | PI departure. | Other (stated, no rule matched) |
| NCT05337735 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare… | Phase 2 | suspended | Apr 20, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05362032 | Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted… | N/A | suspended | May 5, 2022 | OHSU Knight Cancer Institute | Study team paused enrollment | Enrollment / accrual |
| NCT04631744 | Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 2 | terminated | Nov 17, 2020 | Weill Medical College of Cornell University | Low accrual | Enrollment / accrual |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced… | Phase 1 / Phase 2 | terminated | May 26, 2021 | M.D. Anderson Cancer Center | PI requested. | Other (stated, no rule matched) |
| NCT06456411 | Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain… | N/A | terminated | Jun 13, 2024 | Roswell Park Cancer Institute | PI left | Investigator |
| NCT07052760 | Imaging of Solid Tumors Using DLL3 SPECT | Early Phase 1 | withdrawn | Jul 7, 2025 | Thomas Hope | Sponsor funding | Funding |
| NCT04261777 | Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients | Phase 3 | terminated | Feb 10, 2020 | Saving Patients' Lives Medical B.V. | The study was closed prematurely in order to finalise it under EU directive 2001/20/EC, without… | Other (stated, no rule matched) |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT05581589 | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial… | Phase 2 | terminated | Oct 14, 2022 | University of Washington | Study closed to accrual before meeting accrual goal due to major enrollment challenges based on the… | Enrollment / accrual |
| NCT05588609 | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | Phase 2 | terminated | Oct 20, 2022 | Partner Therapeutics, Inc. | Merus terminated the study early due to changes in organizational priorities. | Other (stated, no rule matched) |
| NCT04984343 | Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate…(FORT) | Phase 2 | terminated | Jul 30, 2021 | Weill Medical College of Cornell University | The study was closed prematurely due to low enrollment. | Enrollment / accrual |
| NCT07146919 | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer(ANGELICA) | Phase 1 / Phase 2 | withdrawn | Aug 28, 2025 | Centre Leon Berard | Molecule not available from the laboratory | Other (stated, no rule matched) |
| NCT02555189 | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant,… | Phase 1 / Phase 2 | terminated | Sep 21, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Sponsor-PI decision. An analysis of the primary endpoint concluded that the addition of ribociclib… | Other (stated, no rule matched) |
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or… | Phase 2 | terminated | Aug 22, 2016 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | study closed early due to slow accrual | Enrollment / accrual |
| NCT05700227 | Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for…(ARTIA-Bladder) | N/A | terminated | Jan 26, 2023 | Varian, a Siemens Healthineers Company | Low enrollment | Enrollment / accrual |
| NCT07541066 | Robotic Telesurgery in Urology | N/A | withdrawn | Apr 21, 2026 | Case Comprehensive Cancer Center | PI left institution | Investigator |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | Phase 1 | terminated | May 17, 2023 | Aurigene Discovery Technologies Limited | Patient recruitment problems | Enrollment / accrual |
| NCT06760702 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109…(TEJAS-2) | Phase 2 | terminated | Jan 7, 2025 | Aurigene Discovery Technologies Limited | Patient recruitment problems. | Enrollment / accrual |
| NCT03575611 | Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell… | Phase 2 | suspended | Jul 2, 2018 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05397093 | ITIL-306 in Advanced Solid Tumors | Phase 1 | terminated | May 31, 2022 | Instil Bio | The study was terminated early due to discontinuation of development of the investigational program | Other (stated, no rule matched) |
| NCT05866679 | Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging | Phase 1 | suspended | May 19, 2023 | M.D. Anderson Cancer Center | Suspension | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 3, 2026source: clinicaltrials